Kerman & Co has advised Infinion Biopharma on its investment into Aurum Biosciences
Kerman & Co has advised Infinion Biopharma Limited (Infinion), a biopharmaceutical company focused on developing new, cost-effective and proprietary treatment options for patients, on its strategic investment into Aurum Biosciences Limited (Aurum).
Aurum is a Scottish based clinical stage biopharmaceutical company developing novel oxygen carriers and software for use with MRI. Aurum works closely with the University of Glasgow and NHS Greater Glasgow and Clyde to develop products which it hopes will bring significant lifesaving benefits in the areas of stroke, cardiology, oncology and neuro-degenerative diseases.
The investment round, which was led by Infinion, also included further investment from Scottish Health Innovations Limited, Scottish Enterprise and members of the TRICAPITAL angel investor syndicate.
Commenting on the investment Govind Chavada, Managing Director of Infinion said: “We have worked with Kerman & Co on a number of biotech and MedTech investments in recent years and were delighted to again work with Martin and his team on this transaction. His experience in this sector, as well as his responsiveness and commercial outlook, really helps us in closing deals. We enjoy working with the Kerman team and look forward to doing so on the next transaction.”
Martin O’Donoghue, Partner at Kerman & Co, commented “This was a fantastic deal to be a part of and we are delighted to have been able to advise the Infinion team on such an exciting investment in the bio-science sector. Our venture capital team already has a depth of experience advising businesses in the life science sector, with this transaction further enhancing our credentials. We look forward to working with the Infinion team on further transactions and wish the Infinion and Aurum teams every success for the future.”
The Kerman & Co team was led by corporate Partner, Martin O’Donoghue, who was assisted by Arthur Horsfall (Corporate).
